Mereo BioPharma Group’s (MREO) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

Posted by Francis Steltz on Aug 22nd, 2026

JPMorgan Chase & Co. restated their underweight rating on shares of Mereo BioPharma Group (NASDAQ:MREO – Free Report) in a research note issued to investors on Wednesday, Marketbeat Ratings reports.

Several other brokerages have also issued reports on MREO. Weiss Ratings restated a “sell (e+)” rating on shares of Mereo BioPharma Group in a research note on Thursday, July 2nd. BTIG Research reiterated a “buy” rating and issued a $1.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, August 11th. Zacks Research upgraded Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 10th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Mereo BioPharma Group in a report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $3.25.

Check Out Our Latest Stock Analysis on MREO

Mereo BioPharma Group Price Performance

Shares of Mereo BioPharma Group stock opened at $0.29 on Wednesday. Mereo BioPharma Group has a fifty-two week low of $0.20 and a fifty-two week high of $2.37. The firm has a fifty day moving average price of $0.31 and a two-hundred day moving average price of $0.33. The company has a market cap of $46.35 million, a PE ratio of -7.26 and a beta of 0.36.

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). Analysts expect that Mereo BioPharma Group will post -0.02 earnings per share for the current fiscal year.

Institutional Trading of Mereo BioPharma Group

Institutional investors have recently made changes to their positions in the business. Marex Group plc acquired a new position in Mereo BioPharma Group in the second quarter worth about $27,000. Virtu Financial LLC acquired a new stake in Mereo BioPharma Group during the third quarter valued at approximately $33,000. Forefront Analytics LLC boosted its holdings in Mereo BioPharma Group by 302.2% during the first quarter. Forefront Analytics LLC now owns 127,778 shares of the company’s stock valued at $42,000 after purchasing an additional 96,010 shares in the last quarter. Graham Capital Management L.P. bought a new stake in shares of Mereo BioPharma Group in the 4th quarter valued at approximately $48,000. Finally, Virtus Investment Advisers LLC grew its stake in shares of Mereo BioPharma Group by 199.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 122,595 shares of the company’s stock valued at $51,000 after purchasing an additional 81,665 shares during the period. 62.83% of the stock is currently owned by institutional investors and hedge funds.

Mereo BioPharma Group Company Profile

(Get Free Report)

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.